Ubiquitin-specific Protease 7 Promotes Ferroptosis Via Activation of the P53/TfR1 Pathway in the Rat Hearts After Ischemia/reperfusion
Overview
Biology
General Medicine
Affiliations
Iron overload triggers the ferroptosis in the heart following ischemia/reperfusion (I/R) and transferrin receptor 1 (TfR1) charges the cellular iron uptake. Bioinformatics analysis shows that the three molecules of ubiquitin-specific protease 7 (USP7), p53 and TfR1 form a unique pathway of USP7/p53/TfR1. This study aims to explore whether USP7/p53/TfR1 pathway promotes ferroptosis in rat hearts suffered I/R and the underlying mechanisms. The SD rat hearts were subjected to 1 h-ischemia plus 3 h-reperfusion, showing myocardial injury (increase in creatine kinase release, infarct size, myocardial fiber loss and disarray) and up-regulation of USP7, p53 and TfR1 concomitant with an increase of ferroptosis (reflecting by accumulation of iron and lipid peroxidation while decrease of glutathione peroxidase activity). Inhibition of USP7 activated p53 via suppressing deubiquitination, which led to down-regulation of TfR1, accompanied by the decreased ferroptosis and myocardial I/R injury. Next, H9c2 cells underwent hypoxia/reoxygenation (H/R) in vitro to mimic the myocardial I/R model in vivo. Consistent with the results in vivo, inhibition or knockdown of USP7 reduced the H/R injury (decrease of LDH release and necrosis) and enhanced the ubiquitination of p53 along with the decreased levels of p53 and TfR1 as well as the attenuated ferroptosis (manifesting as the decreased iron content and lipid peroxidation while the increased GPX activity). Knockdown of TfR1 inhibited H/R-induced ferroptosis without p53 deubiquitination. Based on these observations, we conclude that a novel pathway of USP7/p53/TfR1 has been identified in the I/R-treated rat hearts, where up-regulation of USP7promotes ferrptosis via activation of the p53/TfR1 pathway.
Fu X, Zhang X, Wang L, Zhang J, Li W, Qin S BMC Cardiovasc Disord. 2025; 25(1):167.
PMID: 40057674 PMC: 11890518. DOI: 10.1186/s12872-025-04590-2.
New Types of Post-Translational Modification of Proteins in Cardiovascular Diseases.
Fang J, Wu S, Zhao H, Zhou C, Xue L, Lei Z J Cardiovasc Transl Res. 2025; .
PMID: 40032789 DOI: 10.1007/s12265-025-10600-7.
Han L, Zhai W Mol Med Rep. 2025; 31(4).
PMID: 40017132 PMC: 11876945. DOI: 10.3892/mmr.2025.13470.
USP2 reversed cisplatin resistance through p53-mediated ferroptosis in NSCLC.
Gong Y, Li R, Zhang R, Jia L BMC Med Genomics. 2025; 18(1):39.
PMID: 40011884 PMC: 11866681. DOI: 10.1186/s12920-025-02108-5.
Ru Q, Li Y, Zhang X, Chen L, Wu Y, Min J Bone Res. 2025; 13(1):27.
PMID: 40000618 PMC: 11861620. DOI: 10.1038/s41413-024-00398-6.